TEL AVIV, Israel & REYKJAVIK, Iceland--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and biopharmaceutical company Alvotech today announced that they have entered into an exclusive strategic partnership for the commercialization in the U.S. of five biosimilar product candidates. This strategic partnership combines Tevas long-standing commercial presence and extensive infrastructure in the U.S. market with Alvotechs scientific experience and state-of-the-art biologics manufacturing. The initial pipeline contains biosimilar candidates addressing multiple therapeutic areas.
Robert Wessman, Alvotechs founder and Chairman said, We are very proud to announce our strategic alliance with Teva a leading global pharmaceutical company, to accelerate the introduction and adoption of new biosimilar medicines for patients in the U.S. market. This is not only a big moment for the biosimilar industry but also a very special moment for Alvotech, as we continue to join forces with leading global and regional partners around the world.
This commercial partnership with Alvotech will enable Teva to lend its technical expertise in working with the FDA to bring products to the U.S. market while broadening its growing biosimilar portfolio and continuing to leverage its unique cross-functional expertise across both specialty and generic medicines, said Brendan OGrady, Executive Vice President and Head of North America Commercial at Teva. This collaboration is another step in our unwavering commitment to develop and enable access to quality medications to help improve the lives of patients."
Under this partnership agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars, while Teva will be exclusively commercializing the products in the U.S. The originator products of these five candidates currently generate around $35 billion in U.S. sales. The agreement includes an upfront payment, with subsequent milestone payments over the next several years. Teva and Alvotech will share profit from the commercialization of the biosimilars. All other financial terms and product details remain confidential.
About Alvotech
Alvotech is a global biopharmaceutical company focused on the development and manufacture of high quality biosimilars for global markets. We are specialists in biotechnology, seeking to be a global leader in the biosimilar space by delivering high quality, cost-competitive products and services to our partners and to patients worldwide. Our fully integrated approach, with high-quality in-house competencies throughout the value chain, enables the accelerated development of biosimilar medicines.
Alvotechs initial pipeline contains several monoclonal-antibody and fusion-protein biosimilar candidates aimed at treating autoimmunity, oncology, ophthalmology and inflammatory conditions to improve quality of life for patients around the world. For more information, please visit our website, http://www.alvotech.com or follow us on LinkedIn, Twitter and Facebook.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve peoples lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at http://www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the strategic partnership with Alvotech for the commercialization in the U.S. of biosimilar product candidates, which are based on managements current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
the potential that the expected benefits and opportunities related to our collaboration with Alvotech may not be realized or may take longer to realize than expected;
challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals for the biosimilar product candidates;
the commercial success of the biosimilar product candidates, if approved;
our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; competition for our specialty products, especially COPAXONE, our leading medicine, which faces competition from existing and potential additional generic versions, competing glatiramer acetate products and orally-administered alternatives; the uncertainty of commercial success of AJOVY or AUSTEDO; competition from companies with greater resources and capabilities; delays in launches of new products and our ability to achieve expected results from investments in our product pipeline; ability to develop and commercialize biopharmaceutical products; efforts of pharmaceutical companies to limit the use of generics, including through legislation and regulations and the effectiveness of our patents and other measures to protect our intellectual property rights;
our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
our business and operations in general, including: duration, and geographic reach of the COVID-19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general; interruptions in our supply chain, including due to potential effects of the COVID-19 pandemic on our operations and business in geographic locations impacted by the pandemic and on the business operations of our customers and suppliers; adequacy of and our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith; implementation of our restructuring plan announced in December 2017; challenges associated with conducting business globally, including adverse effects of the COVID-19 pandemic, political or economic instability, major hostilities or terrorism; our ability to attract, hire and retain highly skilled personnel; our ability to develop and commercialize additional pharmaceutical products; compliance with anti-corruption sanctions and trade control laws; manufacturing or quality control problems; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; our prospects and opportunities for growth if we sell assets and potential difficulties related to the operation of our new global enterprise resource planning (ERP) system;
compliance, regulatory and litigation matters, including: increased legal and regulatory action in connection with public concern over the abuse of opioid medications in the U.S. and our ability to reach a final resolution of the remaining opioid-related litigation; costs and delays resulting from the extensive governmental regulation to which we are subject or delays in governmental processing time including due to modified government operations due to the COVID-19 pandemic and effects on product and patent approvals; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into S&M practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;
other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;
and other factors discussed in Form 10-K for the year ended December 31, 2019, and subsequent quarterly reports on Form 10-Q, including in the sections captioned "Risk Factors and Forward Looking Statements. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Original post:
- Recruitment - Wikipedia - January 27th, 2017 [January 27th, 2017]
- Resource-based economy and pay-it-forward | The Moneyless ... - January 30th, 2017 [January 30th, 2017]
- A Resource Based Economy - worldsocialism.org - January 30th, 2017 [January 30th, 2017]
- Trump's Flawed Logic Regarding US-Mexico Relations - Fair Observer - February 7th, 2017 [February 7th, 2017]
- Economic freedom achievable through knowledge based economy, innovative technical skill development - President - Asian Tribune - February 7th, 2017 [February 7th, 2017]
- Younger generation inheritors of knowledge-based economy: President - Lanka Business Online - February 7th, 2017 [February 7th, 2017]
- Morguard - 2017 Real Estate Investment Trends to Watch in Canada - Canada NewsWire (press release) - February 7th, 2017 [February 7th, 2017]
- Ask Yourself These Two Questions About America's Economic Future - Fortune - February 8th, 2017 [February 8th, 2017]
- The Informal Economy and Decent Work: A Policy Resource ... - February 8th, 2017 [February 8th, 2017]
- Thunder Bay's population experiencing low growth - Tbnewswatch.com - February 9th, 2017 [February 9th, 2017]
- Substantial investment in agriculture needed to ensure enough food for all - Daily Nation - February 9th, 2017 [February 9th, 2017]
- Can Russia project power while battered by economic woes? - Asia Times - February 9th, 2017 [February 9th, 2017]
- When will Russia finally break its 'resource curse'? - Russia Direct - February 10th, 2017 [February 10th, 2017]
- TEA & TWO SLICES | On Giant Snow Penises And Christy Clark's Shudder-Worthy Interview - Scout Magazine (blog) - February 10th, 2017 [February 10th, 2017]
- Can Russia project power while battered by economic woes ... - MENAFN.COM - February 11th, 2017 [February 11th, 2017]
- Siemens backs Qatar''s economic ambitions with innovation - MENAFN.COM - February 12th, 2017 [February 12th, 2017]
- The 'Dutch disease' reexamined: Resource booms can benefit the wider economy - USAPP American Politics and Policy (blog) - February 13th, 2017 [February 13th, 2017]
- Charles Lawton: Here's a proposal to create real equality of job opportunity - Press Herald - February 14th, 2017 [February 14th, 2017]
- India can't write-off coal-based energy so soon: World Coal Association - Economic Times - February 14th, 2017 [February 14th, 2017]
- The pathologies of redistributive resource transfers - Livemint - February 15th, 2017 [February 15th, 2017]
- Jessica Wright: Well-managed farmland benefits community, watershed - Conway Daily Sun - February 15th, 2017 [February 15th, 2017]
- Evaluate FLSA for its Ability to Keep Pace with Today's Workplace, SHRM Tells House Subcommittee - SHRM - February 16th, 2017 [February 16th, 2017]
- Officials hope fiber optic expansion helps diversify Decatur's economy - The Decatur Daily - February 16th, 2017 [February 16th, 2017]
- 10th Biennial Nehalem Bay Estuary Cleanup set - Tillamook Headlight-Herald - February 16th, 2017 [February 16th, 2017]
- Howard gives Barnett a hand on hustings - The West Australian - February 18th, 2017 [February 18th, 2017]
- EDITORIAL COMMENT: Let's celebrate President's birthday with ... - Chronicle - February 20th, 2017 [February 20th, 2017]
- Kentucky Main Street Program Communities Contributed $110M to State Economy in 2016 - WMKY - February 20th, 2017 [February 20th, 2017]
- GM, Steelcase see a web of opportunity in the circular economy - GreenBiz - February 21st, 2017 [February 21st, 2017]
- The sputtering energy economy: Can it be revved up? - Meridian Star - February 21st, 2017 [February 21st, 2017]
- The difference between Malcolm Turnbull and Justin Trudeau - The Australian Financial Review - February 21st, 2017 [February 21st, 2017]
- In the Face of a Trump Environmental Rollback, California Stands in ... - Yale Environment 360 - February 22nd, 2017 [February 22nd, 2017]
- Report: Boundary Waters nets $77 million from summer visitors - Duluth News Tribune - February 22nd, 2017 [February 22nd, 2017]
- DENIM SPIRIT: An economy based on abundance - Finger Lakes Times - February 23rd, 2017 [February 23rd, 2017]
- HR International to hold confab on African economy - Guardian - February 24th, 2017 [February 24th, 2017]
- Event promotes innovation and technology expansion - News - Castlegar News - February 24th, 2017 [February 24th, 2017]
- The Venus Project Plans to Bring Humanity to the Next Stage of Social Evolution. Here's How. - Futurism - February 24th, 2017 [February 24th, 2017]
- Best returns since 1900? Resource based countries, including ... - Financial Post - February 24th, 2017 [February 24th, 2017]
- Economic growth projected for Saskatchewan in 2017 | Regina ... - Regina Leader-Post - February 24th, 2017 [February 24th, 2017]
- Energy as a Model for US-Mexico Economic Partnership - RealClearEnergy - February 24th, 2017 [February 24th, 2017]
- Science and Technology: Minister says FG will harness natural ... - Pulse Nigeria - February 24th, 2017 [February 24th, 2017]
- Montana Jobs Not Well Positioned - Big Sky Business Journal - Big Sky Business Journal - February 25th, 2017 [February 25th, 2017]
- The future of WA's economy: Life beyond mining - WAtoday - February 27th, 2017 [February 27th, 2017]
- Verdant Zeal set to celebrate decade of providing media solutions - Guardian - February 28th, 2017 [February 28th, 2017]
- Lessons from Canada's scientific resistance - Bulletin of the Atomic Scientists - February 28th, 2017 [February 28th, 2017]
- St Ann can do better Earl Jarrett - Jamaica Gleaner - February 28th, 2017 [February 28th, 2017]
- Firm canvasses technology strategy - The Nation Newspaper - March 3rd, 2017 [March 3rd, 2017]
- Mandryk: Next Saskatchewan boom needs to be from our heritage fund - Regina Leader-Post - March 3rd, 2017 [March 3rd, 2017]
- Bank of Canada channels Al Gore - Toronto Sun - March 3rd, 2017 [March 3rd, 2017]
- Australia's economy has been growing for 25 years straight Quartz - Quartz - March 4th, 2017 [March 4th, 2017]
- The Venus Project envisions a sustainable redesign of our cities and civilization - Inhabitat - March 4th, 2017 [March 4th, 2017]
- State's high-tech hits $1 billion economic milestone - Daily Inter Lake - March 7th, 2017 [March 7th, 2017]
- The startup economy - Canadian Lawyer Magazine - March 7th, 2017 [March 7th, 2017]
- Nehalem Bay Estuary Cleanup - North Coast Citizen - March 7th, 2017 [March 7th, 2017]
- Pipelines to be a 'fundamental' issue for NDP leadership race: Julian - Hill Times (subscription) - March 8th, 2017 [March 8th, 2017]
- Prime Minister Trudeau, no fan of the middle class - Hill Times (subscription) - March 8th, 2017 [March 8th, 2017]
- Finally, Democrats Have A Pro Wrestler In Their Corner - Huffington Post - March 9th, 2017 [March 9th, 2017]
- WA election: Labor outlines campaign costings and debt reduction plan - ABC Online - March 9th, 2017 [March 9th, 2017]
- WA election: Death threats, One Nation legal action, stadium stoush campaign trail action - ABC Online - March 9th, 2017 [March 9th, 2017]
- Russia, Israeli firm agree to invest $100 mln in Russia's dairy industry - Reuters - March 10th, 2017 [March 10th, 2017]
- Maine deserves a chance to capitalize on the North Woods monument - Bangor Daily News - March 10th, 2017 [March 10th, 2017]
- MAN, RMRDC, others to promote resource-based MSMEs,funding - The Nation Newspaper - March 10th, 2017 [March 10th, 2017]
- Jobs, education focus of Gov. Brown's Prineville visit - KTVZ - KTVZ - March 10th, 2017 [March 10th, 2017]
- HIKE NETARTS BAYOCEAN SPIT - North Coast Citizen - March 11th, 2017 [March 11th, 2017]
- Jobs versus or for the environment? - Budgeeter News - March 11th, 2017 [March 11th, 2017]
- Canada Invests $325 Million in the Fish and Seafood Sector - Yahoo Finance - March 11th, 2017 [March 11th, 2017]
- We are taking steps to overhaul economy through knowledge-based ... - TheNewsGuru (satire) (press release) (blog) - March 11th, 2017 [March 11th, 2017]
- Canada Invests $325 Million in the Fish and Seafood Sector - Marketwired (press release) - March 12th, 2017 [March 12th, 2017]
- Saskatchewan gender, immigrant wage gaps among widest in Canada - Saskatoon StarPhoenix - April 8th, 2017 [April 8th, 2017]
- Week in Film: Endless LOLs, an Acid Western, and Great Advice ... - Bedford + Bowery - April 8th, 2017 [April 8th, 2017]
- Famous fish the focus of 'steelhead ecology' hike - Tillamook Headlight-Herald - April 8th, 2017 [April 8th, 2017]
- 'Explore Nature' sets Cape Lookout hike - Tillamook Headlight-Herald - April 8th, 2017 [April 8th, 2017]
- Califonria Lawmakers approve billion dollar gas tax | KBAK - Bakersfield Now - April 8th, 2017 [April 8th, 2017]
- Globe editorial: On pipelines, Ottawa must have the final say - The ... - The Globe and Mail - June 6th, 2017 [June 6th, 2017]
- Politics biggest determinant of economic future, says Page - Tbnewswatch.com - June 6th, 2017 [June 6th, 2017]
- Our Turn: Pass SB 129, save 900 New Hampshire jobs - Concord Monitor - June 6th, 2017 [June 6th, 2017]
- We'll Always Have Paris: Trump's Impact On The Climate Agreement - HuffPost - June 6th, 2017 [June 6th, 2017]
- A strategy that will make Canadian innovation flourish - The Globe and Mail - June 6th, 2017 [June 6th, 2017]
- Ocean Conference Side Events Highlight Cooperation on SDG 14 ... - IISD Reporting Services - June 7th, 2017 [June 7th, 2017]
- We must tap 'blue economy' for progress - Daily Nation - June 8th, 2017 [June 8th, 2017]
- Minnesota Power Proposes Next Step in EnergyForward Plan - POWER magazine - June 9th, 2017 [June 9th, 2017]